雷珠单抗与康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的短期疗效比较

Comparison of Short-term Efficacy of Lucentis and Conbercept in the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

目的比较雷珠单抗与康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的短期疗效。方法选择2017年1月~2018年3月我院收治非缺血性视网膜分支静脉阻塞继发黄斑水肿患者46例(46眼),按随机数字表法分为A组和B组,每组23例。A组给予雷珠单抗注射,B组给予康柏西普组注射,比较两组术前、术后1、3个月最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)及并发症发生情况。结果术后1、3个月,两组BCVA、CMT均高于术前,差异有统计学意义(P<0.05);两组BCVA、CMT比较,差异无统计学意义(P>0.05)。两组并发症发生率比较,差异无统计学意义(P>0.05)。结论玻璃体腔注射雷珠单抗或康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿患者可有效提高BCVA、减少CMT,无明显全身或眼部重大不良反应,其疗效相当。

Objective To compare the short-term efficacy of Lucentis and Conbercept in the treatment of macular edema secondary to retinal vein occlusion.Methods From January 2017 to March 2018,46 patients(46 eyes)with non-ischemic branch retinal vein occlusion secondary macular edema were treated in our hospital,and according to the random number table method,they were divided into group A and group B,23 examples in each group.Group A was injected with Lucentis,and group B was injected with Conbercept and the best corrected visual acuity(BCVA),retinal thickness in macular fovea(CMT)and complications between the two groups 1 and 3 months after operation.Results At 1 and 3 months after operation,the BCVA and CMT in the two groups were higher than before surgery,the difference was statistically significant(P<0.05).There was no significant difference in BCVA and CMT between the two groups(P>0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion Intravitreal injection of Lucentis or Conbercept in patients with secondary macular edema due to branch retinal vein occlusion can effectively increase BCVA and reduce CMT,without significant systemic or ocular major adverse effects,and its efficacy is comparable.